cancer

Researchers have discovered that administering immunotherapy drugs for lung cancer in the morning can significantly improve patient survival rates. This approach leverages the body's circadian rhythms, which influence immune cell activity. The findings suggest a simple timing adjustment could enhance treatment effectiveness without added costs.